Klox Technologies
Klox is a private biomedical technology innovator that targets specific skin and soft tissue conditions by controlling the benefits of fluorescence generated energy to penetrate and manage the skin from within. The unique products we bring to the market stimulate the skin’s own biological processes and repair mechanisms, which demonstrate high safety and efficacy, helping clinicians improve patient outcomes without compromise.
Our technology induces Fluorescence Biomodulation (FB), which has shown to impact cellular signaling pathways in the skin. We research, develop, and commercialize solutions based on our fluorescence-generating technology for a growing and aging population that is seeking more effective and less invasive options to improve their health.
Explore our Technology
Klox products are applied to the skin and activated by LED light for a short exposure period lasting under ten minutes.
Light interacts with light absorbing molecules (LAM) embedded within the Klox gel to generate fluorescent energy.
Klox is a medical device company that transforms lives through its innovative Fluorescence Biomodulation technology. Read more.
Wound Care
Wound care specialists and patients require innovation that can predictably heal chronic wounds. Advanced wound care generates more than $9 billion in costs, driven by difficulties in hard to heal wounds, an aging population and an increasing demand for homecare treatments.
LumiHeal™ is a globally patented wound care solution, supported by scientific evidence (five clinical studies) and a CE mark in Europe.
Partnering
Klox invests in the development, innovation and delivery of launch-ready technology and products. To commercialize our Fluorescence Biomodulation technology, we rely on investment capital and long-term business partners with expertise in our therapeutic categories.
We are offering our high growth LumiHeal™ wound care system and our late-stage Phovia™ veterinary system for strategic partnerships.
Trusted Collaborators
At Klox, we always strive to build and invest in our science, technology, and engineering expertise. To challenge the conventions of the industry, we extend our capabilities by collaborating with leading professionals and cutting-edge scientific facilities, wherever they may be. Our extended network is critical for maintaining vitality and scientific rigor in our mission to bring Fluorescence Biomodulation to patients in need.
News & Events
June 10-15, 2019
World Congress of Dermatology – Milan, Italy
June 5-7, 2019
European Wound Management Association – Gothenburg, Sweden
May 16-17, 2019
VetCon – Cork, Ireland
May 3-4, 2019
The European Society of Lymphology Meeting – Brussels, Belgium
March 20-21, 2019
Medical Technology Enterprise Consortium – South Carolina, USA
March 15-17, 2019
La Chirurgia Estetica– Florence, Italy
March 8, 2019
Publication in the SPIE Photonics West 2019 Conference Proceedings – Management of all three phases of wound healing through the induction of fluorescence biomodulation using fluorescence light energy
March 7, 2019
LumiHeal was granted the Canadian Medical Device License (MDL) for “the management of post-surgical closed wounds and to help in the prevention of hypertrophic scars and post-surgical wound complications in patients 18 years and older”
March 1, 2019
Fluorescence Biomodulation has been added to various sections in the Journal of Wound Care’s 2019 peer-reviewed International Consensus Document – Implementing TIMERS: the race against hard-to-heal wounds
February 26-27, 2019
Animal Health Investment Europe – London, England
February 2-7, 2019
SPIE Photonics West – San Francisco, USA
January 30, 2019
LumiHeal Newsletter – Updates On Our Lead Wound Care Product
January 20-22, 2019
Journées Cicatrisations – Paris, France
January 7-10, 2019
J.P. Morgan Healthcare Conference – San Francisco, USA
November 5-7, 2018
Wounds UK – Harrogate, UK
November 4, 2018
Publication in the peer-reviewed Journal of Wound Care – Evaluation of fluorescence biomodulation in the real-life management of chronic wounds: The EUREKA trial
September 24-26, 2018
The MedTech Conference – Philadelphia, USA
September 12-14, 2018
The European Pressure Ulcer Advisory Panel – Rome, Italy
July 2, 2018
Klox announces positive top-line results from a pivotal study of Phovia™ for the management of Canine Deep Pyoderma – See Full Press Release
June 13-14, 2018
Wound Care from Innovations to Clinical Trials (WCICT) – Edinburgh, United Kingdom
June 4-7, 2018
BIO International Convention – Boston, USA
May 9-11, 2018
The European Wound Management Association (EWMA) – Krakow, Poland
May 2-3, 2018
The Bloom Burton & Co. Healthcare Investor Conference – Toronto, Canada
April 25-29, 2018
The Symposium on Advanced Wound Care Spring (SAWC) – Charlotte, North Carolina